<unk>  was found to be useful and feasible in the multidisciplinary management of many solid tumors but further studies are needed to determine the benefit more precisely. Single-institution experiences have suggested a role of<unk>  e.g. in brain tumors and cerebral metastases, locally advanced and recurrent rectal cancer, skin cancer, retroperitoneal sarcoma, pancreatic cancer, and selected gynaecologic and genitourinary malignancies. For local recurrences, irradiation with<unk>  is, besides brachytherapy, the only radiotherapeutic option if repeated EBRT is no longer possible. Generally, the normal tissue tolerance does not allow a second full-dose course of EBRT, even after years. Breast cancer On 25 July 2014, the UK National Institute for Health and Care Excellence (NICE) gave provisional recommendation for the use of TARGIT<unk>  with Intrabeam in the UK National Health Service. The 2015 update of guidelines of the Association of Gynecological Oncology (AGO), an autonomous community of the German Society of Gynecology and Obstetrics (DGGG) and the German Cancer Society includes TARGIT<unk>  during lumpectomy as a recommended option for women with a T1, Grade 1 or 2, ER positive breast cancer.
Intraoperative radiation therapy
Intraoperative electron radiation therapy
Neoadjuvant therapy
Targeted intra-operative radiotherapy
Adjuvant therapy
Nerve-sparing surgery
Selective internal radiation therapy
Prostate brachytherapy